{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:36Z","timestamp":1761863436862},"reference-count":20,"publisher":"Informa UK Limited","issue":"18","license":[{"start":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T00:00:00Z","timestamp":1436400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,9,30]]},"DOI":"10.2217\/fon.15.163","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T15:32:01Z","timestamp":1436455921000},"page":"2553-2562","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Impact of Sorafenib Dosing on Outcome from the European Patient Subset of the GIDEON Study"],"prefix":"10.1080","volume":"11","author":[{"given":"Bruno","family":"Daniele","sequence":"first","affiliation":[{"name":"Department of Oncology, G Rummo Hospital, Benevento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adina","family":"Croitoru","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Papandreou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital of Larissa, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Centre Hospitalier Universitaire de Nancy, Universit\u00e9 Henri Poincar\u00e9\u2013Nancy, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[{"name":"Services des Maladies de l\u2019Appareil Digestif, H\u00f4pital Claude Huriez, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Serejo","sequence":"additional","affiliation":[{"name":"Center of Gastroenterology, Liver Unit, Hospital de Santa Maria, Faculty of Medicine, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"St\u00e5l","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Karolinska University Hospital, Huddinge, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Turnes","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital de Montecelo, Complejo Hospitalario de Pontevedra, Pontevedra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9pato-Gastroent\u00e9rologie, Universit\u00e9 Pierre et Marie Curie and Hospital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Bodoky","sequence":"additional","affiliation":[{"name":"Department of Oncology, St L\u00e1szl\u00f3 Teaching Hospital, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,7,9]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0013"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3441"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.124"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.014"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000336082"},{"key":"e_1_3_3_13_1","unstructured":"ClinicalTrials Database: NCT00812175. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00812175."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02414.x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02940.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4001","article-title":"Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction","volume":"29","author":"Marrero JA","year":"2011","unstructured":"Marrero JA , LencioniR, KudoMet al. Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction. J. Clin. Oncol.29(Suppl.), Abstract 4001 (2011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-95"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0143"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.030"},{"issue":"4","key":"e_1_3_3_21_1","article-title":"Final analysis of overall survival per subgroups of HCC patients in the prospective, non-interventional INSIGHT study treated with sorafenib","volume":"25","author":"Ganten TM","year":"2014","unstructured":"Ganten TM , StauberR, SchottEet al. Final analysis of overall survival per subgroups of HCC patients in the prospective, non-interventional INSIGHT study treated with sorafenib. Ann. Oncol.25(Suppl. 4), Abstract 728P (2014).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24644"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:23Z","timestamp":1719125123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,9]]},"references-count":20,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2015,9,30]]}},"alternative-id":["10.2217\/fon.15.163"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.163","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}